Altimmune Inc
NASDAQ:ALT
Altimmune Inc
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
IMPACT Data Milestone: Altimmune will report 48-week data from the Phase II IMPACT trial of pemvidutide for MASH before year-end, a major upcoming catalyst.
FDA Progress: The company secured an in-person end-of-Phase II meeting with the FDA for MASH, based on strong 24-week data, to align on Phase III trial design.
RECLAIM Trial Enrollment: Phase II RECLAIM trial in alcohol use disorder (AUD) completed enrollment nearly 5 months ahead of schedule, highlighting strong demand.
Financial Strength: Cash position rose to $211 million at September 30, 2025, up 60% year-to-date, with $127 million raised in the first nine months.
R&D Spend Down: Q3 R&D expenses fell to $15 million from $19.8 million last year due to timing of development costs.
Leadership Expansion: Key hires include new Chief Medical, Commercial, and Legal Officers to support next growth phase.
Market & Payer Feedback: Early market research with European payers and physicians was positive, with 70-80% of physicians indicating high likelihood to prescribe pemvidutide.
Flexible Phase III Planning: Phase III MASH program to be designed for flexibility, able to incorporate NITs and AI-based biopsy endpoints as regulatory guidance evolves.
